Cargando…
LMD-02. Cerebrospinal Fluid Diversion for Metastatic Leptomeningeal Carcinomatosis: Palliative, Procedural and Oncologic Outcomes
BACKGROUND: Leptomeningeal disease (LMD) occurs in 3–5% of patients with solid metastatic tumors and often portends a severe prognosis including symptomatic hydrocephalus and intracranial hypertension. Cerebrospinal fluid (CSF) shunting can provide symptomatic relief in this patient subset; however,...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351259/ http://dx.doi.org/10.1093/noajnl/vdab071.027 |
_version_ | 1783735936063897600 |
---|---|
author | Bander, Evan D Yuan, Melissa Reiner, Anne S Garton, Andrew Panageas, Katherine S Brennan, Cameron W Tabar, Viviane Moss, Nelson S |
author_facet | Bander, Evan D Yuan, Melissa Reiner, Anne S Garton, Andrew Panageas, Katherine S Brennan, Cameron W Tabar, Viviane Moss, Nelson S |
author_sort | Bander, Evan D |
collection | PubMed |
description | BACKGROUND: Leptomeningeal disease (LMD) occurs in 3–5% of patients with solid metastatic tumors and often portends a severe prognosis including symptomatic hydrocephalus and intracranial hypertension. Cerebrospinal fluid (CSF) shunting can provide symptomatic relief in this patient subset; however, few studies have examined the role of shunting in the palliation, prognosis and overall oncologic care of these patients. OBJECTIVE: To identify and evaluate risk factors associated with prognosis after CSF diversion and assess surgical, symptomatic and oncologic outcomes in this population. METHODS: A retrospective study was conducted on patients with solid-malignancy LMD treated with a shunt at an NCI-designated Comprehensive Cancer Center between 2010–2019. RESULTS: One hundred and ninety patients with metastatic LMD underwent CSF diversion. Overall survival was 4.14 months from LMD diagnosis (95%CI:3.29–4.70) and 2.43 months (95%CI:2.01–3.09) from shunting. KPS at time of shunting and BrM number at LMD diagnosis demonstrated significant associations with survival (HR=0.66; 95%CI[0.51–0.86], p=0.002; HR=1.40; 95%CI[1.01–1.93] per 10 BrM, p=0.04, respectively). Eighty-three percent of patients experienced symptomatic relief, and 79% were discharged home or to rehabilitation facilities post-shunting. Post-shunt, 56% of patients received additional systemic therapy or started or completed WBRT. Complications included infection (5%), symptomatic subdural hygroma/hematoma (6.3%), and shunt externalization/removal/repair (8%). Abdominal seeding was not identified. CONCLUSIONS: CSF diversion for LMD with hydrocephalus and intracranial hypertension secondary to metastasis can achieve symptomatic relief, hospital discharge, and return to further oncologic therapy, with a complication profile unique to this pathophysiology. However, decision-making in this population must incorporate end-of-life goals of care given limited prognosis. |
format | Online Article Text |
id | pubmed-8351259 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-83512592021-08-09 LMD-02. Cerebrospinal Fluid Diversion for Metastatic Leptomeningeal Carcinomatosis: Palliative, Procedural and Oncologic Outcomes Bander, Evan D Yuan, Melissa Reiner, Anne S Garton, Andrew Panageas, Katherine S Brennan, Cameron W Tabar, Viviane Moss, Nelson S Neurooncol Adv Supplement Abstracts BACKGROUND: Leptomeningeal disease (LMD) occurs in 3–5% of patients with solid metastatic tumors and often portends a severe prognosis including symptomatic hydrocephalus and intracranial hypertension. Cerebrospinal fluid (CSF) shunting can provide symptomatic relief in this patient subset; however, few studies have examined the role of shunting in the palliation, prognosis and overall oncologic care of these patients. OBJECTIVE: To identify and evaluate risk factors associated with prognosis after CSF diversion and assess surgical, symptomatic and oncologic outcomes in this population. METHODS: A retrospective study was conducted on patients with solid-malignancy LMD treated with a shunt at an NCI-designated Comprehensive Cancer Center between 2010–2019. RESULTS: One hundred and ninety patients with metastatic LMD underwent CSF diversion. Overall survival was 4.14 months from LMD diagnosis (95%CI:3.29–4.70) and 2.43 months (95%CI:2.01–3.09) from shunting. KPS at time of shunting and BrM number at LMD diagnosis demonstrated significant associations with survival (HR=0.66; 95%CI[0.51–0.86], p=0.002; HR=1.40; 95%CI[1.01–1.93] per 10 BrM, p=0.04, respectively). Eighty-three percent of patients experienced symptomatic relief, and 79% were discharged home or to rehabilitation facilities post-shunting. Post-shunt, 56% of patients received additional systemic therapy or started or completed WBRT. Complications included infection (5%), symptomatic subdural hygroma/hematoma (6.3%), and shunt externalization/removal/repair (8%). Abdominal seeding was not identified. CONCLUSIONS: CSF diversion for LMD with hydrocephalus and intracranial hypertension secondary to metastasis can achieve symptomatic relief, hospital discharge, and return to further oncologic therapy, with a complication profile unique to this pathophysiology. However, decision-making in this population must incorporate end-of-life goals of care given limited prognosis. Oxford University Press 2021-08-09 /pmc/articles/PMC8351259/ http://dx.doi.org/10.1093/noajnl/vdab071.027 Text en © The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Supplement Abstracts Bander, Evan D Yuan, Melissa Reiner, Anne S Garton, Andrew Panageas, Katherine S Brennan, Cameron W Tabar, Viviane Moss, Nelson S LMD-02. Cerebrospinal Fluid Diversion for Metastatic Leptomeningeal Carcinomatosis: Palliative, Procedural and Oncologic Outcomes |
title | LMD-02. Cerebrospinal Fluid Diversion for Metastatic Leptomeningeal Carcinomatosis: Palliative, Procedural and Oncologic Outcomes |
title_full | LMD-02. Cerebrospinal Fluid Diversion for Metastatic Leptomeningeal Carcinomatosis: Palliative, Procedural and Oncologic Outcomes |
title_fullStr | LMD-02. Cerebrospinal Fluid Diversion for Metastatic Leptomeningeal Carcinomatosis: Palliative, Procedural and Oncologic Outcomes |
title_full_unstemmed | LMD-02. Cerebrospinal Fluid Diversion for Metastatic Leptomeningeal Carcinomatosis: Palliative, Procedural and Oncologic Outcomes |
title_short | LMD-02. Cerebrospinal Fluid Diversion for Metastatic Leptomeningeal Carcinomatosis: Palliative, Procedural and Oncologic Outcomes |
title_sort | lmd-02. cerebrospinal fluid diversion for metastatic leptomeningeal carcinomatosis: palliative, procedural and oncologic outcomes |
topic | Supplement Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351259/ http://dx.doi.org/10.1093/noajnl/vdab071.027 |
work_keys_str_mv | AT banderevand lmd02cerebrospinalfluiddiversionformetastaticleptomeningealcarcinomatosispalliativeproceduralandoncologicoutcomes AT yuanmelissa lmd02cerebrospinalfluiddiversionformetastaticleptomeningealcarcinomatosispalliativeproceduralandoncologicoutcomes AT reinerannes lmd02cerebrospinalfluiddiversionformetastaticleptomeningealcarcinomatosispalliativeproceduralandoncologicoutcomes AT gartonandrew lmd02cerebrospinalfluiddiversionformetastaticleptomeningealcarcinomatosispalliativeproceduralandoncologicoutcomes AT panageaskatherines lmd02cerebrospinalfluiddiversionformetastaticleptomeningealcarcinomatosispalliativeproceduralandoncologicoutcomes AT brennancameronw lmd02cerebrospinalfluiddiversionformetastaticleptomeningealcarcinomatosispalliativeproceduralandoncologicoutcomes AT tabarviviane lmd02cerebrospinalfluiddiversionformetastaticleptomeningealcarcinomatosispalliativeproceduralandoncologicoutcomes AT mossnelsons lmd02cerebrospinalfluiddiversionformetastaticleptomeningealcarcinomatosispalliativeproceduralandoncologicoutcomes |